Siglec-E Antibody (F-7): sc-377477

Siglec-E Antibody (F-7) is a mouse monoclonal IgM antibody that detects Siglec-E of mouse origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-Siglec-E antibody (F-7) is available in a non-conjugated form, allowing for versatile applications in various experimental settings. Siglec-E, also known as Cd170, Siglec5, Siglec9, or mSiglec-E, is a 467 amino acid protein that plays a crucial role in the immune system by mediating sialic acid-dependent cell adhesion. Siglec-E is primarily localized to the cell membrane and features one immunoglobulin-like V-type domain and two immunoglobulin-like C2-type domains, which are essential for function. Siglec-E is expressed at high levels in the heart, liver, and spleen, with lower expression in the lung and kidney, highlighting importance in immune responses in these organs. Siglec-E exists as a disulfide-linked homodimer, enhancing ability to bind sialylated ligands and facilitating cell-cell interactions. Siglec-E undergoes post-translational modifications, including phosphorylation, which can significantly influence binding capabilities and interactions with other proteins, thereby impacting immune signaling pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Siglec-E Antibody (F-7) References:

1. Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions.  |  Connolly, NP., et al. 2002. Br J Haematol. 119: 221-38. PMID: 12358929
2. Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes.  |  Erickson-Miller, CL., et al. 2003. Exp Hematol. 31: 382-8. PMID: 12763136
3. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.  |  Virgo, P., et al. 2003. Br J Haematol. 123: 420-30. PMID: 14617000
4. Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.  |  Avril, T., et al. 2005. J Biol Chem. 280: 19843-51. PMID: 15769739
5. Sialoside-binding macrophage lectins in phagocytosis of apoptotic bodies.  |  Rapoport, EM., et al. 2005. Biochemistry (Mosc). 70: 330-8. PMID: 15823088
6. Siglec-E promotes β2-integrin-dependent NADPH oxidase activation to suppress neutrophil recruitment to the lung.  |  McMillan, SJ., et al. 2014. J Biol Chem. 289: 20370-6. PMID: 24895121
7. Siglec-E Negatively Regulates the Activation of TLR4 by Controlling Its Endocytosis.  |  Wu, Y., et al. 2016. J Immunol. 197: 3336-3347. PMID: 27619995
8. Siglec-E retards atherosclerosis by inhibiting CD36-mediated foam cell formation.  |  Hsu, YW., et al. 2021. J Biomed Sci. 28: 5. PMID: 33397354
9. Ablation of Siglec-E augments brain inflammation and ischemic injury.  |  Li, L., et al. 2022. J Neuroinflammation. 19: 191. PMID: 35858866
10. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.  |  Wang, X., et al. 2022. Cell Metab. 34: 1088-1103.e6. PMID: 35921817
11. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.  |  Smith, BAH., et al. 2023. Proc Natl Acad Sci U S A. 120: e2215376120. PMID: 36897988
12. Siglec-F+ neutrophils in the spleen induce immunosuppression following acute infection.  |  Liao, C., et al. 2024. Theranostics. 14: 2589-2604. PMID: 38646647

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Siglec-E Antibody (F-7) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-Siglec-E Antibody (F-7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Siglec-E Antibody (F-7) Specifications

Alternate Product Name: Siglec-E

Product Clone Name: F-7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM kappa light chain

Amino Acids: 371-403

Epitope Target: Siglec-E

Epitope Species: mouse

Product Reactivity/Detection: Siglec-E

Species Reactivity/Detection: mouse

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for Siglec-E Antibody (F-7): P: Blocking Peptide

The preferred Siglec-5 antibody is Siglec-5 Antibody (H-7): sc-377005.